Two-Thirds of Patients With Lupus Likely to Take COVID-19 Vaccine
A survey from the Lupus Research Alliance announced that two-thirds of people with lupus are willing to receive a COVID-19 vaccine.
Lupus
Identifying Risk Factors for Osteonecrosis in Patients With Systemic Lupus Erythematosus
Researchers identified predictors of osteonecrosis in patients with systemic lupus erythematosus.
Hydroxychloroquine Levels Linked to Thrombosis Risk in Lupus
For patients with SLE lower hydroxychloroquine blood levels are associated with a higher risk for thrombotic events.
Rituximab Plus Cyclophosphamide Followed by Belimumab Safe for Refractory Lupus Nephritis Treatment
Researchers evaluated the safety, mechanism of action, and preliminary efficacy of rituximab and cyclophosphamide followed by belimumab in the treatment of refractory lupus nephritis.
Factors Associated With Rapid Progression to End-Stage Kidney Disease in Lupus Nephritis Identified
A small study suggests that poor medication compliance and certain histopathologic features may be associated with development of end-stage kidney disease within 3 years of lupus nephritis diagnosis.
Using Multivariate Assay Panel Results in Cost Savings in Diagnosis of SLE
Researchers evaluated the potential budget impact of using multivariate assay panel vs standard diagnostic laboratory tests to diagnose systemic lupus erythematosus.
Belimumab Approved for Lupus Nephritis
Belimumab is already indicated for the treatment of active, autoantibody-positive systemic lupus erythematosus in individuals aged 5 years and over.
African American vs Caucasian Patients With Lupus, VTE Events Less Likely to Have Significant aPL Profile
Study authors examined the differences in antiphospholipid antibody prevalence among Caucasian and African American patients with SLE and venous thromboembolic events.
A Closer Look at Cardiovascular Disease Risk in Patients With Systemic Lupus Erythematosus
An overview of the increased risk for cardiovascular disease in patients with systemic lupus erythematosus.
Pre-Exposure to Hydroxychloroquine May Not Prevent COVID-19 Mortality in Patients With Rheumatologic Disease
Researchers evaluated the effectiveness of hydroxychloroquine for the prevention of COVID-19 mortality in patients with rheumatologic disease.
-
Loading...
-
Loading...
Next post in General Rheumatology
